# A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

> **NCT01288911** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 375 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** enzalutamide
- **DRUG:** bicalutamide

## Key facts

- **NCT ID:** NCT01288911
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-22
- **Primary completion:** 2014-10-19
- **Final completion:** 2017-11-08
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01288911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01288911, "A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01288911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*